PATIENT INFORMATION LEAFLET
Adenosina Kabi 3 mg/ml injectable solution in pre-filled syringe
Adenosina
Read this leaflet carefully before you start using this medicine because it contains important information for you.
Adenosina Kabi contains a medication called adenosine that belongs to a group of medications called antiarrhythmics.
Adenosina Kabi reduces electrical impulses between the upper and lower chambers of the heart. This slows down rapid or irregular heartbeats called "arrhythmias".
Adenosina Kabi is used in adults:
Do not use Adenosina Kabi if
Do not use this medication if any of the above contraindications affect you. If you are unsure, consult your doctor, nurse, or pharmacist before Adenosina Kabi is administered to you.Adenosina Kabi.
Warnings and precautions
Consult your doctor or nurse before using Adenosina Kabi if you have:
Treatment with adenosine should be discontinued if you observe a very slow heart rate (severe bradycardia), respiratory insufficiency, a potentially fatal heart problem (asystole), severe chest pain (angina), or very low blood pressure (severe hypotension).
If you are unsure whether any of the above effects affect you, consult your doctor or nurse before Adenosina Kabi is administered to you.
Use of Adenosina Kabi with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
This is because adenosine may affect how some medications work. Some of these medications may also change the effect of adenosine.
In particular, inform your doctor, nurse, or pharmacist if you are taking any of the following medications:
Use of Adenosina Kabi with food and drinks
It is recommended to avoid foods or drinks that contain caffeine, such as tea, coffee, chocolate, and cola for at least 12 hours before Adenosina Kabi is administered.
Pregnancy, breastfeeding, and fertility
Consult your doctor or pharmacist before using this medication if:
If you are pregnant or breastfeeding, or think you may be pregnant, or have plans to become pregnant, consult your doctor or pharmacist before using this medication.
Adenosina Kabi contains sodium
This medication contains less than 1 mmolof sodium (23 mg) per ml; it is essentially “sodium-free”.
How Adenosina Kabi Should Be Administered
Adenosina Kabi is a medication for use in hospitals.
It will be administered to you by a doctor or nurse through an intravenous injection.
Your heart and blood pressure will be closely monitored.
What Amount of Adenosina Kabi Is Administered
If you are unsure why you are being administered Adenosina Kabi or have questions about the amount being administered, ask your doctor, nurse, or pharmacist.
Adults
Children
These preloaded syringes are not suitable for the administration of small volumes required for children.
Older Adults
See the adult dose recommendation.
If You Have Received More Adenosina Kabi Than You Should Have
As this medication is administered by a doctor or nurse, it is unlikely that you will receive more than the intended amount. Your doctor will carefully calculate how much Adenosina Kabi you should receive.
If you receive more medication than you should, the following effects may occur:
Your doctor will continuously monitor your heart during the process.
As the time that adenosine remains in the blood is very short, any adverse effect due to an overdose of Adenosina Kabi will cease rapidly when the injection is stopped. Sometimes, you may need an injection of a medication called aminophylline or theophylline to prevent any possible adverse effect.
If you have any other questions about the use of this medication, ask your doctor or nurse.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
While you are being given Adenosina Kabi, you may experience the following side effects.
If any of the following side effects worsen, inform your doctor or nurse immediately and they will decide whether you should continue with the injection or not.
Side effects usually resolve in a few seconds or minutes after the injection has finished, but you should inform your doctor or nurse if you experience any of them.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Your doctor, nurse or pharmacist will keep this medication in a safe place where children cannot see it or reach it.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Do not refrigerate.
This medication is for single use and should be used immediately after opening. Any unused remainder of the pre-filled syringe should be discarded.
Adenosina Kabi should not be used if, before administering the medication, your doctor or nurse observe particles in the solution or any change in the color of the solution.
The pre-filled syringe should be discarded if the appearance of the medication has changed.
Medications should not be thrown down the drain or in the trash. Your doctor or nurse will dispose of the packaging and unused medications. This will help protect the environment.
Composition of Adenosina Kabi
Appearance of the product and contents of the pack
Adenosina Kabi is a transparent and colorless injectable solution.
Adenosina Kabi is supplied in packs containing 1, 6 or 10 pre-filled syringes.
Only some pack sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder:
Fresenius Kabi España, S.A.U.
C/ Marina, 16-18, 08005 Barcelona
Spain
Manufacturer responsible:
Fresenius Kabi Austria GmbH
Hafnerstrasse 36, 8055 Graz
8055 Graz
Austria
This medicinal product is authorized in the Member States of the European Economic Area and the United Kingdom (Northern Ireland) with the following names:
Name ofName of medicinal product
Member State
BelgiumAdenosine Fresenius Kabi 3 mg/ml, solution for injection in a pre-filled syringe
DenmarkAdenosin Fresenius Kabi
ItalyAdenosina Kabi
IrelandAdenosine 3 mg/ml solution for injection in pre-filled syringe
NetherlandsAdenosine Fresenius Kabi 3 mg/ml, solution for injection in a pre-filled syringe
PolandAdenosine Kabi
PortugalAdenosina Kabi
SpainAdenosina Kabi 3mg/ml solution for injection in pre-filled syringe
United KingdomAdenosine 3 mg/ml solution for injection in pre-filled syringe
(Northern Ireland)
Last update of the summary of product characteristics: February 2024
The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
-------------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals
Adenosina Kabi 3 mg/ml solution for injection in pre-filled syringe
For more details on this medicinal product, consult the technical dossier
Qualitative and quantitative composition
1 ml of solution contains 3 mg of adenosine.
Each pre-filled syringe of single-dose 1 ml contains 3 mg of adenosine.
Each pre-filled syringe of single-dose 2 ml contains 6 mg of adenosine.
Each pre-filled syringe of single-dose 4 ml contains 12 mg of adenosine
To consult the complete list of excipients, see section 6.1.
Pharmaceutical form
Solution for injection in pre-filled syringe
Therapeutic indications
Conversion to normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with abnormal conduction pathways (Wolff-Parkinson-White syndrome).
Diagnostic indications
Aid to diagnosis of supraventricular tachycardias with wide or narrow complexes. Although Adenosina Kabi does not reverse atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, slowing of AV conduction facilitates diagnosis of atrial activity.
Sensitization in endocardial electrophysiological investigations.
Dosage and administration
Adenosina Kabi is only for usein hospitals with monitoring and cardiorespiratory resuscitation equipment available for immediate use if necessary.
Adenosina Kabi should only be used in facilities with cardiac monitoring. Patients who, after a certain dose, present with high-grade AV block should not receive additional doses.
Dosage
Adults:
Initial dose:3 mg administered as a bolus intravenous injection (2-second injection)
Second dose:if the first dose does not stop supraventricular tachycardia in 1 or 2 minutes, 6 mg should be administered as a bolus intravenous injection.
Third dose:if the second dose does not stop supraventricular tachycardia in 1 or 2 minutes, 12 mg should be administered as a bolus intravenous injection.
No additional or higher doses are recommended.
Pediatric population
These pre-filled syringes are not suitable for pediatric use.
Geriatric population
See recommended dosage for adults.
Diagnostic dose
The ascending dosage indicated above may be administered until sufficient diagnostic information is obtained.
Administration
Adenosina should be administered by intravenous bolus injection (IV) directly into a vein or through an intravenous catheter. If administered through an intravenous catheter, the injection should be made as close to the catheter as possible, followed by a rapid flush with physiological saline. If administered through a peripheral vein, a larger diameter cannula should be used.
Pharmacological properties
Excipients
Sodium chloride.
Water for injection.
Incompatibilities
In the absence of compatibility studies, this medicinal product should not be mixed with other medicinal products.
Shelf-life
36 months
The medicinal product should be used immediately after opening.
Special precautions for storage
Do not refrigerate.
Nature and contents of the container
Pre-filled syringe of plastic 1 ml containing 1 ml (3 mg/1 ml) with halobutilo protective cap.
Packs containing:
1 pre-filled syringe
6 pre-filled syringes
10 pre-filled syringes
Pre-filled syringe of plastic 5 ml containing 2 ml (6 mg/2 ml) with halobutilo protective cap.
Packs containing:
1 pre-filled syringe
6 pre-filled syringes
10 pre-filled syringes
Pre-filled syringe of plastic 5 ml containing 4 ml (12 mg/4 ml) with halobutilo protective cap.
Packs containing:
1 pre-filled syringe
6 pre-filled syringes
10 pre-filled syringes
Only some pack sizes may be marketed.
Special precautions for disposal
Do not use if particles or change in color of the solution are observed.
The disposal of unused medicinal product and all materials that have been in contact with it, should be carried out in accordance with local regulations.
Instructions for use of the pre-filled syringe:
When using the pre-filled syringe of plastic 5 ml containing 4 ml (12 mg of adenosine / 4 ml) to administer only a dose of 6 mg, first 2 ml of the syringe should be discarded before administering the remaining 2 ml to the patient.
Use an aseptic technique
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.